Continuous Risk Assessment of Late and Term Preeclampsia Throughout Pregnancy: A Retrospective Cohort Study
<i>Background and Objectives</i>: To evaluate the diagnostic accuracy of widely available biomarkers longitudinally measured throughout pregnancy to predict all and term (delivery at ≥37 weeks) preeclampsia (PE). <i>Materials and Methods</i>: This is a longitudinal retrospect...
Saved in:
| Main Authors: | Valeria Rolle, Petya Chaveeva, Ander Diaz-Navarro, Irene Fernández-Buhigas, Diana Cuenca-Gómez, Tanya Tilkova, Belén Santacruz, Teresa Pérez, Maria M. Gil |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/60/12/1909 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Case Report of Influence of Free Tyrosine Kinase/Placental Growth Factor (SFLT-1/PLGF) Ratio Test for Preeclampsia on Clinical Decision Making in Screening Positive Women
by: Polina Vasileva, et al.
Published: (2019-12-01) -
Impact of parity and pre-pregnancy BMI on second-trimester sFlt-1 and PlGF levels in normotensive pregnancies
by: Motoaki Kinugawa, et al.
Published: (2025-12-01) -
Angiogenic Biomarkers: Are They Good Tools to Predict Perinatal Outcomes in Hypertensive Disorders of Pregnancy? A Retrospective Cohort Study
by: Magdalena Bednarek-Jędrzejek, et al.
Published: (2025-03-01) -
Serum sFlt-1/PlGF ratio combined with ANXA2 correlates with adverse pregnancy outcomes in women with suspected preeclampsia
by: YaNuan Chen, et al.
Published: (2025-12-01) -
Placental growth factor at 24–28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial
by: Marta Ricart, et al.
Published: (2024-11-01)